TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Hospital Association, four safety-net hospitals and the Maine Hospital Association have sued the Trump administration over a planned change to the 340B drug discount program. The model, scheduled to begin January 1, would require hospitals to pay full drug prices upfront and seek rebates later; the groups say implementation could cost hospitals more than $1 billion annually. A court decision is expected before the change is due to take effect.
The American Hospital Association, four safety-net hospitals and the Maine Hospital Association have sued the Trump administration over a planned change to the 340B drug discount program, asking a federal court to stop a rebate model scheduled to begin January 1, 2027. The groups say hospitals could face more than $1 billion in annual administrative costs while paying full drug prices upfront instead of receiving discounts before dispensing medicines.
Under the existing system, qualifying hospitals obtain 340B drugs at a discount before providing them to patients. The report describes typical discounts as about 13% for generic drugs and 23% for brand-name drugs. Under the planned model, hospitals would first pay the regular price, then submit a claim for a rebate after dispensing the medicine.
The lawsuit seeks to cancel the new approach and restore the current arrangement. The American Hospital Association says its estimates put the potential annual administrative burden above $1 billion, in addition to the upfront cash hospitals would need to purchase drugs. That cost estimate is the hospitals’ assessment, not a court finding.
The Health Resources and Services Administration, which administers the program, reports that covered entities spent $100 billion on 340B drugs in 2025, up from $81.4 billion in 2024 and $66.3 billion in 2023. Those figures measure spending on 340B drugs; by themselves, they do not establish how much hospitals saved or how they used the funds.
Upfront Drug Costs Put Pressure on Hospitals
The dispute concerns both the timing of drug payments and the administrative work required to claim discounts. If hospitals must pay list prices before seeking rebates, they may need more cash available to buy medicines while awaiting repayment. The hospital groups argue that this could redirect resources from patient services to purchasing and processing claims, particularly for providers with limited financial flexibility.
The issue reaches beyond hospital budgets because 340B participants include providers serving low-income and underserved communities. The AHA says program savings support medication access, behavioral health and oncology care, and other community services. Those are the association’s descriptions of how participants use the savings; the lawsuit’s claims and the eventual court ruling will determine whether the administration can implement this particular model.
Drugmakers and hospitals disagree over whether the program is being used as intended. Pharmaceutical manufacturers say the program has grown too large and argue that some hospitals profit from discounted medicines without adequate safeguards for how savings are spent. The competing positions leave the court to assess the legality of the proposed change, while broader questions about program oversight remain part of the policy debate.
340B drug discount program medical supplies
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
A Repeated Fight Over 340B Rebates
The 340B program provides discounted medicines to eligible hospitals and other covered entities. Congress created it to help those providers stretch resources for patients with limited means. For nearly 35 years, hospitals have generally received discounts when purchasing eligible drugs rather than paying full price and applying for reimbursement later.
This is not the administration’s first effort to introduce a rebate-based approach. According to the report, a similar proposal announced last year was blocked by courts. Maureen Testoni, head of 340B Health, said the current plan is effectively a repeat of that earlier effort and argued that rebates could allow drugmakers to delay or reduce the resources hospitals receive. The prior court action does not, on its own, determine the outcome of the current case.
PhRMA, the trade association representing drug companies, says hospitals can buy medicines at very low prices and charge more, and contends that there are insufficient guardrails on how program-related funds are spent. The hospital groups counter that growth in 340B drug spending reflects factors including the shift toward outpatient care and the use of costly specialty medicines. These are opposing arguments from interested parties, not findings established by the lawsuit.
“The proposed shift from upfront 340B discounts to a rebate-based system would place significant financial pressure and administrative burdens on hospitals and clinics that rely on 340B savings to support essential patient care services.”
— Guy Hudson, president and CEO of Northern Light Health
Court Ruling and Costs Remain Open
The court has not yet ruled on whether the administration may proceed with the rebate model. The briefing period is expected to conclude in mid-November 2026, after which the judge will decide whether oral arguments are needed. A decision is expected before the planned January 1 start date, but the precise timing and outcome are not confirmed.
The record provided does not detail the full mechanics of rebate claims, how quickly payments would be made, or how the administration would handle disputed or delayed claims. The projected annual cost above $1 billion is attributed to hospital estimates; the source does not provide an independent assessment or a breakdown of that figure. The broader claims about hospital profits, patient benefits and oversight are disputed by the parties.
Briefing Ends Before January Start
The parties are due to finish briefing the case in mid-November. The judge will then determine whether to hold oral arguments and is expected to issue a decision before January 1, 2027, when the new payment model is scheduled to begin. The lawsuit’s request is to block the change and return to upfront discounts.
Until the court acts, the planned start date remains the administration’s schedule, while the legal challenge is unresolved. The ruling will determine whether the rebate model can take effect on that timetable; the available information does not establish what further administrative or legal steps either side would take afterward.
Key Questions
What change to the 340B program is being challenged?
The administration plans to replace discounts applied when hospitals purchase drugs with a rebate system. Hospitals would pay the regular price upfront and seek a rebate after dispensing the medicine.
Who filed the lawsuit?
The plaintiffs named in the report are the American Hospital Association, four safety-net hospitals and the Maine Hospital Association. They are asking the court to cancel the planned change and restore the existing approach.
When is the rebate model scheduled to start?
The model is scheduled to take effect on January 1, 2027. Its implementation depends on the unresolved lawsuit and any court order.
How much could implementation cost hospitals?
The American Hospital Association says estimates indicate the model could impose more than $1 billion in annual administrative costs. That figure is the association’s estimate; the source does not provide an independent verification or detailed calculation.
When is the court expected to decide?
Briefing is expected to finish in mid-November 2026. A decision is expected before January 1, 2027, though the exact date and whether oral arguments will be held are not known.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
